ERBB2 and endometrial cancer: Type II endometrial cancer is characterized by a high number of tumour suppressor p53 mutations [20], and other low-frequency genomic alterations such as tumour suppressor cyclin-dependent kinase inhibitor 2A (p16) inactivation and Erb-B2 receptor tyrosine kinase 2 (HER-2/neu) over-activation [17].